AstraZeneca secures FDA priority review for Farxiga
AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce…
Read More...
Read More...
